Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ), Sarepta Therapeutics Inc (SRPT), Edwards Lifesciences Corp (EW): 3 Health Care Investment Ideas for June

If you heeded the old adage to “sell in May and go away” this year, you’re probably second-guessing your decision now. The major indexes climbed during May — and health-care stocks as a group performed even better. With share prices of so many companies near their 52-week highs, should the new saying be “sell in June before stocks swoon?” Maybe so, but there’s no way to know when or if the market will pull back. Here are three health-care investment ideas for June for investors still looking to buy.

Something big

If you’re looking for a big health-care company to add to your portfolio, look no further than Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) continues to experience strong growth with its pharmaceuticals, diagnostics, and medical device business segments. Its consumer products unit lags behind the other segments but still generates hefty profits.

Johnson & Johnson (NYSE:JNJ)

The latest news from Johnson & Johnson (NYSE:JNJ) isn’t good, though. The company is recalling 32 million packages of its Cilest birth control pills in Europe, Asia and Latin America. Similar problems have plagued Johnson & Johnson (NYSE:JNJ) over the last couple of years, with the company recalling blood glucose meters, contact lenses, heart devices, insulin pump cartridges, and over-the-counter drugs. These past recalls led megainvestor Warren Buffett to cut back on his holdings in the company. Buffett said that J&J has “a lot of wonderful products” and “a wonderful balance sheet” but that the company had made “too many mistakes.”

However, I don’t think the latest recall will weigh too heavily on the stock. Johnson & Johnson shares have slipped almost 5% from the highs hit in mid-May, but this minor pullback started 2 weeks ago before the recall was announced. The stock is still up nearly 19% year-to-date.

I think Johnson & Johnson (NYSE:JNJ)’s solid-if-not-spectacular growth prospects combined with a nice 3.1% dividend yield make the stock a good pick. As my Foolish colleague Brian Orelli said recently, “For long-term investors, there’s rarely a bad time to buy Johnson & Johnson stock.”

Something bold

Buying shares in Sarepta Therapeutics Inc (NASDAQ:SRPT) requires more boldness from investors than buying J&J stock, but I still think it’s a smart idea over the long run. Sarepta Therapeutics Inc (NASDAQ:SRPT) is up 33% for the year, but shares have sank nearly 13% in the past few weeks.

You need to be bold to buy Sarepta Therapeutics Inc (NASDAQ:SRPT) because the stock could drift lower before it bounces back. Concerns abound about whether eteplirsen — the company’s drug that treats rare Duchenne muscular dystrophy, or DMD — will gain accelerated approval from the Food and Drug Administration. If eteplirsen doesn’t get an FDA nod for the accelerated track, Sarepta Therapeutics Inc (NASDAQ:SRPT) will need to move forward with a phase 3 trial for the drug.

Regardless of what happens in the near term, eteplirsen seems poised to be a game-changer for DMD patients. I think Sarepta Therapeutics Inc (NASDAQ:SRPT) shares will ultimately take off again in a major way. I’m not the only one who thinks this way. Billionaire George Soros upped his stake in Sarepta recently.

Something beaten down

While J&J and Sarepta have enjoyed success so far in 2013, that’s not the case for Edwards Lifesciences Corp (NYSE:EW). Shares of the medical device company are down 29% year-to-date. However, I suspect that this beaten-down stock remains a good investing option.

Edwards’ shares plummeted in April after the company missed earnings estimates and lowered full-year guidance. This miss and more pessimistic outlook stemmed largely from sluggish U.S. sales of the company’s Sapien heart valves. Edwards Lifesciences Corp (NYSE:EW)’ CEO Michael Mussallem said that the lower sales were “primarily the result of evolving economics for some hospitals and still developing capacity of both hospitals and their heart teams.” However, Mussallem added that the company’s “estimate of the size of the U.S. transcatheter valve opportunity for the longer-term remains unchanged.”

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.